Inter-species comparison of microsomal reductive transformation of biologically active benfluron N-oxide

Drug Metabolism and Drug Interactions

Volumn 14, Issue 4, 1998, Pages 235-250

  Skalova L ^a   Nobilis, M ^b   Szotakova B ^a   Wsol V ^a   Kvasnickova E ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Benfluron N oxide; Cytochrome P450 reductase activity; Cytostatic drugs; Microsomal reduction; N oxides

Indexed keywords

BENFLURON; BENFLURON N OXIDE; CYTOCHROME P450 REDUCTASE; TERTIARY AMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; GUINEA PIG; MALE; METABOLITE; MICROSOME; MOUSE; NONHUMAN; RABBIT; RAT; REDUCTION; SPECIES DIFFERENCE;

EID: 0031875412     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.1998.14.4.235     Document Type: Article

References (36)

1. Kvasničková E, Nobilis M, Hais IM. Chromatographic characterization of in vitro metabolites of 5[2-(N,N′-dimethylamino)ethoxy]-7-oxo-7H-benzo[c]-fluorene. J Chromatogr 1984; 295: 201-209.
2. Kvasničková E, Hais IM, Nobilis M. Relationship between NADPH and NADPH as cosubstrates of N-oxidation of the cytostatic benfluron by FMO. Prog Pharmacol Clin Toxicol 1991; 7: 146.
3. Skálová L, Nobilis M, Szotáková B, Trejtnar F, Kvasničková E. In vitro and in vivo biotransformation of benfluron N-oxide, a biologically active metabolite of a potential cytostatic. Exp Toxic Pathol 1996; 48: 366-370.
4. Nobilis M, Kvasničková E, Šroler A, Hais IM. Elimination of benfluron and its metabolites in the faeces and urine of rats. Drug Metab Drug Interact 1991; 9: 225-240.
5. Vančurová I et al. Patent application no. PCT/CS88/239413.
6. Testa B. Reduction catalyzed by cytochrome P450 and other oxidoreductases. In: Testa B, Caldwell J, eds. The Metabolism of Drugs and Other Xenobiotics. Biochemistry of Redox Reactions. London: Academic Press, 1995; 398-447.
7. Benakis A, Halpaap B. Reductive metabolism and toxicological implications. Exp Toxic Pathol 1996; 48: 25-33.
8. Fink-Gremmels J, Van Miert AS. Species differences in biotransformation. Conventional models in unconventional animal species. Exp Toxic Pathol 1996; 48: 120-127.
9. Valles B, Schiller CD, Coassolo P, De Sousa G, Rahmani R. Metabolism of mofarotene in hepatocytes and liver microsomes from different species. Drug Metab Dispos 1995; 23: 1051-1057.
10. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin C phenol reagent. J Biol Chem 1951; 193: 165-275.
11. Omura T, Sato R. The carbon-monoxide-binding pigment of liver microsomes. II. Solubilization, purification, properties. J Biol Chem 1964; 239: 2379-2385.
12. Nobilis M, Anzenbacher P, Pastera J, Svoboda Z, Hrubý K, Kvìtina J, Ubik K, Trejtnar F. Study of biotransformation of a potential benzo[c]fluorene antineoplastic using HPLC with high-speed-scanning UV detection. J Chromatogr B 1996; 681: 143-151.
13. Raffa R, Haslego ML, Maryanoff CA, Villani FJ, Codd EE, Connelly CD, Martinez RP, Schupsky JJ, Buben JA, Wu VN, Takacs AN, Mckown LA. Unexpected antinociceptive effect of the N-oxide (RWJ 38705) of tramadol hydrochloride. J Pharmacol Exp Ther 1996; 278: 1098-1104.
14. Wislocki PG, Miwa GT, Lu AYH. Reactions catalyzed by cytochrome P450 system. In: Jakoby WB, ed. Enzymatic Basis of Detoxication. London: Academic Press, 1980.
15. Goeptar RA, Scheerens H, Vermeulen NPE. Oxygen and xenobiotic reductase activities of cytochrome P450. Crit Rev Toxicol 1995; 25: 25-65.
16. Patterson AV, Barham HM, Chinje EC, Adams GE, Harris AL, Stratford IJ. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 1995; 72: 1144-1150.
17. Elwell JH, Siim BG, Evans JW, Brown JM. Adaptation of human tumor cells to tirapazamine under aerobic conditions. Biochem Pharmacol 1997; 54: 249-257.
18. Tercel M, Wilson WR, Denny WA. Hypoxia-selective antitumor agents. 11. Chlorambucil N-oxide: a reappraisal of its synthesis, stability, and selective toxicity for hypoxic cells. J Med Chem 1995; 38: 1247-1252.
19. Patterson LH. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Metastasis Rev 1993; 12: 119-134.
20. Riley RJ, Workman P. Enzymology of the reduction of the potent enzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD(P)H: (Quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochem Pharmacol 1992; 43: 167-174.
21. Wilson WR, Van Zijl P, Denny WA. Bis-bioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. Int J Radiat Oncol Biol Phys 1992; 22: 693-696.
22. Fitzsimmons SA, Lewis AD, Riley RJ, Workman P. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN59075, SR4233) to a DNA-damaging species: a direct role for NADPH: cytochrome P450 oxidoreductase. Carcinogenesis 1994; 15: 1503-1510.
23. Walton MI, Wolf CR, Workman P. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 1992; 44: 251-259.
24. 5 reductase. Biochem Pharmacol 1996; 51: 829-837.
25. 2-insensitive NADH-benzamidoxime reductase. J Biol Chem 1997; 272: 19615-19620.
26. Pröpper D, Maser E Carbonyl reduction of daunorubicin in rabbit liver and heart. Pharmacol Toxicol 1997; 80: 240-245.
27. Maser E, Bannenberg G. The purification of 11β-hydroxysteroid dehydrogenase from mouse liver microsomes. J Steroid Biochem Mol Biol 1994; 48: 257-263.
28. Rekka EA, Soldan M, Belai I, Netter KJ, Maser E. Biotransformation and detoxification of insecticidal metyrapone analogues by carbonyl reduction in the human liver. Xenobiotica 1996; 26: 1221-1229.
29. Maser E, Richter E, Friebertshäuser J. The identification of 11-beta-hydroxysteroid dehydrogenase as carbonyl reductase of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Eur J Biochem 1996; 238: 484-489.
30. Maser E, Bannenberg G. 11β-Hydroxysteroid dehydrogenase mediates reductive metabolism of xenobiotic carbonyl compounds. Biochem Pharmacol 1994; 47: 1805-1812.
31. Apanovitsch D, Walz FG Jr. Adult-male-specific S-warfarin (11S-OH) and progesterone (20β-OH) keto-reductases in rat hepatic microsomes are not identical. Biochim Biophys Acta 1996; 1291: 16-26.
32. Imamura Y, Kimura R, Kozono Y, Otagiri M. Strain- and sex-related differences of acetohexamide reductase activities in liver microsomes and cytosol of rats: The Wistar-Imamichi strain lacks the male-specific microsomal enzyme activity. Life Sci 1995; 57: 1811-1817.
33. Imamura Y, Takada H, Kimura R, Mori Y, Otagiri M. Inheritance of aceto-hexamide reductase activities in liver microsomes and cytosol of rats. Life Sci 1996; 59: 2201-2208.
34. Oppermann UC, Maser E, Mangoura SA, Netter KJ. Heterogeneity of carbonyl reduction in subcellular fractions and different organs in rodents. Biochem Pharmacol 1991; 42 (Suppl): 189-195.
35. Maser E, Hahnemann B, Legrum W, Oppermann U, Netter KJ. The influence of cytochrome P-450 inducers on carbonyl reduction in mouse liver. Arch Toxicol 1991; 14 (Suppl): 188-192.
36. Anzenbacher P, Souček P, Gut I, Hrubý K, Anzenbacherová E, Květina J. Cytochrome PATO3A, the most important enzyme of drug metabolism in human liver, is present in minipig liver microsomes in similar content and activity to human samples. ISSX Proc 1997; 11: 231.